William Blair analyst Myles Minter has maintained their bullish stance on ALNY stock, giving a Buy rating on January 30.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors, including Alnylam’s stronger-than-expected fourth-quarter results and clear progress toward sustained profitability. The company delivered revenue modestly ahead of his forecast, with TTR franchise growth driven by continued momentum of Amvuttra in ATTR-cardiomyopathy, helping to validate management’s long-term growth outlook.
He also highlights that Alnylam achieved profitability on both a non-GAAP and GAAP basis while continuing to build its cash position, which he views as a key de-risking milestone. In addition, updated 2026 guidance for product sales, collaborations, and royalties, alongside disciplined R&D and SG&A spending and a planned $250 million manufacturing expansion, reinforces his conviction in durable double-digit revenue growth and supports the Buy recommendation.
In another report released on January 30, Bank of America Securities also reiterated a Buy rating on the stock with a $462.00 price target.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.